Conference Coverage

The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

Dolutegravir Monotherapy: Still No Longer Recommended in Either Research or Clinical Practice

Although treatment guidelines since 2016 recommend against further research into the use of dolutegravir monotherapy, it was disconcerting to have two oral presentations at AIDS 2018 reporting studies that still continued after the 2016 recommendatio...

By Simon Collins for HIV i-Base

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

By Polly Clayden for HIV i-Base

Dolutegravir/3TC Dual Therapy as Switch Option in Multiple Studies

Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.

By Simon Collins for HIV i-Base

Dolutegravir Outperforms Lopinavir/Ritonavir Second-Line: Interim Results From the DAWNING Study

Dolutegravir (DTG) was superior to lopinavir/ritonavir (LPV/r) in a comparison of DTG-based regimen versus the WHO-recommended second-line regimen.

By Polly Clayden for HIV i-Base

Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity

Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.

By Polly Clayden for HIV i-Base

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

By Myles Helfand

Two-Drug HIV Treatment Regimens Effective in Latest Studies

"This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens," says Kimberly Smith, M.D., M.P.H.

By Barbara Jungwirth

Dolutegravir Monotherapy Studies Halted Due to Integrase Resistance: Dual Therapy Studies Continue

Several studies at CROI 2017 reported a similar conclusion: reducing ART to dolutegravir monotherapy should be stopped.

By Simon Collins for HIV i-Base

Dolutegravir Exposure Increases When Fixed-Dose Combination Tablets Are Crushed

Dolutegravir exposure was higher after crushing the originator fixed-dose combination tablet and after crushing was followed by enteral nutrition, compared to the whole tablet.

By Polly Clayden for HIV i-Base